ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2835

Association between Changes in Gene Signature Expression and Disease Activity in Systemic Lupus Erythematosus

Michelle Petri1, Wei Fu1, Ann Ranger2, Normand Allaire2, Patrick Cullen3 and Laurence S Magder4, 1Medicine (Rheumatology), Johns Hopkins University School of Medicine, Baltimore, MD, 2Biogen Idec, Cambridge, MA, 3Biogen Idec, Cambridge, MD, 4Epidemiology and Public health, University of Maryland School of Medicine, Baltimore, MD

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Disease Activity, Gene Expression and systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Tuesday, October 23, 2018

Session Title: 5T090 ACR Abstract: SLE–Clinical III: Translational Aspects (2832–2837)

Session Type: ACR Concurrent Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose: We assessed the stability of BAFF, interferon, plasma cell and LDG neutrophil gene expression signatures over time, and whether changes in gene expression coincided with changes in SLE disease activity.

Methods: 243 patients with SLE were evaluated for disease activity, serological parameters and peripheral blood gene signatures in clinic visits that occurred between 2009 and 2012. 143 SLE patients contributed two visits, 40 patients contributed three visits and 60 patients contributed four or more visits. Levels of the BAFF gene transcript, plasma cell signature, Interferon (IFN) signature and the low density granulocytes (LDG)-associated neutrophil gene signature were assessed in PAX-gene-preserved peripheral blood by global microarray. For multi-gene signatures, the geometric mean of component expression was calculated. The stability of repeated measures of gene expression was quantified using intra-class correlation coefficients (ICC). SLE disease activity was measured using the Physicians Global Assessment (PGA) and the SELENA-SLEDAI index and its components. Using a mixed effects regression model we assessed: 1) the association between a patient’s average gene signature expression over time and disease activity, and 2) the association between a patient’s changes in gene expression over time and changes in disease activity.

Results: Gene expression signatures showed more within-person stability than systolic blood pressure. The IFN signature exhibited the most stability. Patients with high levels of BAFF and IFN transcripts tended to have significantly higher levels of musculoskeletal disease, skin disease, anti-dsDNA, and ESR, and lower levels of complement. However, changes in BAFF or IFN gene signatures were not associated with changes in disease activity. The same associations were seen between the LDG gene signature and disease activity. However, when LDG increased, complement tended to increase. Patients with high levels of plasma cell gene signature tended to have higher levels of anti-dsDNA and lower levels of complement. However, unlike the other gene signatures, changes in plasma cell gene signature significantly coincided with changes in anti-dsDNA and complement.

Conclusion: The gene expression signatures were relatively stable within patients over time. BAFF and IFN gene expression were markers of patients with generally higher disease activity, but changes in these gene signatures did not coincide with changes in disease activity. The plasma cell gene signature expression tracked with the traditional SLE serologic markers of anti-dsDNA and complement.


Disclosure: M. Petri, EMD Serono, 5,Exagen, 2,Janssen, 5,GSK, 5,AstraZeneca, 2,Inova Diagnostic, 5,Novartis, 5,Amgen Inc., 5,Decision Resources, 5,Medscape, 5,Eli Lilly and Co., 5,Quintiles, 5; W. Fu, None; A. Ranger, Biogen Idec, 3; N. Allaire, Biogen Idec, 3; P. Cullen, Biogen Idec, 1, 3; L. S. Magder, None.

To cite this abstract in AMA style:

Petri M, Fu W, Ranger A, Allaire N, Cullen P, Magder LS. Association between Changes in Gene Signature Expression and Disease Activity in Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 10). https://acrabstracts.org/abstract/association-between-changes-in-gene-signature-expression-and-disease-activity-in-systemic-lupus-erythematosus/. Accessed January 20, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/association-between-changes-in-gene-signature-expression-and-disease-activity-in-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.